Y-mAbs Therapeutics Inc (YMAB) FinancialsYMABFinancialY-mAbs Therapeutics Inc

Y-mAbs Therapeutics Inc (YMAB) generates its revenue primarily from DANYELZA, which accounts for 100.0% of total sales, equivalent to $19.52M. Understanding this concentration is critical for investors evaluating how YMAB navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Y-mAbs Therapeutics Inc maintains a gross margin of 86.11%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -28.70%, while the net margin is -16.59%. These profitability ratios, combined with a Return on Equity (ROE) of -24.31%, provide a clear picture of how effectively YMAB converts its operational activities into shareholder value.

In the context of the broader market, YMAB competes directly with industry leaders such as CGEM and FULC. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, YMAB's gross margin of 86.11% stands against CGEM's N/A and FULC's N/A. Such benchmarking helps identify whether Y-mAbs Therapeutics Inc is trading at a premium or discount relative to its financial performance.